Innovent Biologics

blocks stack target climb build arrow meet

Awaiting regulator verdict, Innovent posts latest psoriasis win

Innovent has posted another win for its IL-23 contender to the likes of Tremfya and Skyrizi while the company awaits a decision by Chinese regulators.

James Waldron Oct 29, 2024 9:50am

ESMO: Innovent links cytokine to colorectal cancer responses

Sep 18, 2024 9:53am

Innovent links IL-2 fusion protein to responses in small study

Jun 14, 2024 10:00am

Innovent's Tepezza rival closer to China nod after phase 3 win

Feb 20, 2024 8:38am

target reach ladder climb meet win beat competition

Next-gen Lilly obesity drug secures first phase 3 win for Innovent

Jan 9, 2024 5:29am

Innovent’s rival to AbbVie, J&J psoriasis drugs clears phase 2

Aug 10, 2022 6:50am